The use of combination antiretroviral therapy in HIV-infected patients

Annals of Pharmacotherapy

Volumn 33, Issue 2, 1999, Pages 198-209

  Holtzer, Christopher D ^a,b   Roland, Michelle ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UCSF AIDS Program San Francisco General Hospital Bldg 80 Ward 86 ^*

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Nonnucleoside reverse transcriptase inhibitors; Nucleoside analogs; Protease inhibitors

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0033014009     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18145     Document Type: Review

References (61)

1. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998; updated recommendations of the International AIDS society - USA panel. JAMA 1998;280:78-86.
2. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Federal Register 1998(June 17):1-50.
3. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infections: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
4. Concorde coordinating committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate vs. deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
5. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
6. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE. et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med 1995;122:24-32.
7. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333:1662-9.
8. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335: 1091-8.
9. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside momitherapy with combination therapy in HIV-infected adults with CD4 cells counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
10. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334: 1011-7.
11. Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir plus Hivid (abstract). In: Programs and Abstracts of the XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
12. Sension M, Farthing C, Pattison TP, Pilson R, Siemon-Hryczyk. Fortovase (saquinavir soft gel capsule: SQV-SGC) in combination with AZT and 3TC in antiretroviral naive HIV-1 infected patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
13. Landman F, Damond P, Detruchis C, Gaudebout C, Girard P-M, Gorin I, et al. Ritonavir, stavudine and didanosine as triple combination treatment in anti-retroviral naive patients (abstract). 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
14. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study group. Lancet 1997;351:543-9.
15. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
16. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725-33.
17. Clumeck N, for the AVANTI study group. AVANTI 3. A randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs. AZT/3TC/nelfinavir in antiretroviral naive patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
18. Clendeninn B, Quart B, Anderson M, Knowles M, Chang Y. Analysis of long-term virologic data from the Viracept 511 protocol using 3 HIV-RNA assays (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
19. Saag M, Knowles M, Chang Y, Chapman S, Clendeninn B, for the Viracept Cooperative Study group. Durable effect of Viracept in triple combination therapy (abstract). 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
20. Deeks S, Grant R, Horton C, Simmonds N, Follansbee S, Eastman S. Virologic effect of RTV plus SQV in subjects who have failed IDV (abstract). 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
21. Tebas P, Kane E, Klebert M, Simpson J, Powderly WG, Henry K. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
22. Gallant JE, Heath-Chiozzi M, Raines C, Anderson R, Katz T, Fields C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
23. Opravil M for the SPICE study team. Study of protease inhibitor combinations in Europe (SPICE); saquinavir soft gelatin capsules and nelfinavir in HIV-infected individuals (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
24. Riddler S, Stein D, Mayers D, Bach M, Havlir D, Kahn J, et al. Durable clinical anti-HIV-1 activity (48 weeks) and tolerability (24 weeks) for DMP 266 in combination with indinavir (IDV) [DMP 266-003, cohort [V] (abstract). Infectious Diseases Society of America 35th Meeting, San Francisco, CA, September 13-16, 1997.
25. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.
26. Friedland GH, Fischl MA, Pollard RB, Griffith BP, Hughes M, Bassett R, et al. Delavirdine mesylate (DLV) in two and three drug combinations with zidovudine (ZDV) and didanosine (ddI), (ACTG 261) (abstract). Infectious Diseases Society of America 35th Meeting, San Francisco, CA, September 13-16, 1997.
27. Package insert. Invirase (saquinavir). Nutley, NJ: Roche Laboratories, 1997.
28. Package insert. Fortovase (saquinavir). Nutley, NJ: Roche Laboratories, 1997.
29. Carr A, Samaras K, Burton S, Law M, Freund J, Chishol DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
30. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997;31:1040-58.
31. Package insert. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 1997.
32. Package insert. Crixivan (indinavir). West Point, PA: Merck & Co., Inc., 1997.
33. Package insert. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., 1997.
34. Merrill DP, Manion DJ, Chou TC, Hirsch MS. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Infect Dis 1997;176:265-8.
35. Batisse D, Salmon-Seron D, Karmochkine M, Ginsburg C, Castiel P, Raguinet G, et al. Efficacy and safety of RTV and SQV in combination in Pl experienced patients (abstract). 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
36. Havlir DV, Riddler S, Squires K, Winslow D, Kerr B, Ngyuyen BY, et al. Co-administration of indinavir and nelfinavir in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
37. Hsu A, Granneman GR, Japour A, Cao G, Locke C, Carothers L, et al. Evaluation of potential ritonavir and indinavir combination bid regimens (abstract). 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
38. Holtzer CD, Coleman RL. Use of nonnucleoside reverse transcriptase inhibitors - a brief review. Am J Hosp Pharm 1998;55:283-7.
39. Package insert. Viramune (nevirapine). Columbus, OH: Roxane Laboratories, Inc., 1996.
40. Package insert. Rescriptor (delavirdine). Kalamazoo, MI: Pharmacia & Upjohn, 1997.
41. Package insert. Sustiva (efavirenz). Wilmington, DE: DuPont Pharma. 1998.
42. BHIV Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
43. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
44. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A. Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
45. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: viron clearance rate, infected cell life span and viral generation time. Science 1996;271:1582-6.
46. Kaufmann D, Pantaleo G, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-4.
47. Ventura SJ, Peter KD, Martin JA, Maurer JD. Births and deaths: United States, 1996. Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service, CDC, National Center for Health Statistics, 1997. (Monthly vital statistics report; vol. 45, no. 12, suppl).
48. Centers for Disease Control and Prevention (CDC). Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:165-92.
49. Hollzer CD, Jacobson MA, Hadley WK, Huang L, Stanely HD, Montanti R, et al. Decline in specific opportunistic infections at the San Francisco General Hospital: 1994-1997 (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
50. Murphy R, El-Sadr W, Cheung T, Luskin-Hawke R, Yuri T, Neaton J, et al. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
51. Holtzer C, Deeks SG. Impact of HIV-1 protease inhibitors on the cost of treating HIV/AIDS patients. Drug Benefit Trends 1998;10(Jan):27-31.
52. McCollum M, Klaus B, La Rue R, Bessesen M. HAART reduced overall cost of HIV care at DVMAC-Denver (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
53. Melnick D, Greiner D, Little P, Melnick K. Impact of aggressive management of HIV infections on clinical outcome and cost of care within a health maintenance organization (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
54. Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-5.
55. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1. Nature 1995; 373:117-22.
56. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir and/or ritonavir in an urban health clinic (abstract). 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
57. Vanhove GF, Shapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996;276:1955-6.
58. Cohen V, Maggio C, Triplett JW, Klimas NG, Dickinsoon G. Relationship between antiretroviral prescription compliance and immunologic, virologic, and clinical outcomes (abstract). ACCP Annual Meeting, November 1997.
59. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997;11:1665-70.
60. Conner EM, Sperling RS, Gelber R, Kiseleu P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331: 1173-80.
61. Department of Health and Human Services. Public Health Service Task Force Recommendation for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-2):1-30.